Citations

Clear

4 citation(s) found for "Dickinson, Stephanie".

Plasma Biomarkers of Senescence in Cholestatic Liver Disease: A Signature of Risk Stratification and Progression
O'Hara, Steven P. , Bogert, Pamela Tietz, Dickinson, Stephanie, Chen, Xiwei , Netto, Jair Machado Espindola, Kirkland, James L., Tchkonia, Tamara, Ashraf, Humza M. , Morgenthaler, Olivia , Ali, Ahmad H. , Gores, Gregory J., LaRusso, Nicholas, O’Hara, Steven P. , Bogert, Pamela S., Dickinson, Stephanie, Allison, David B. , Espíndola‐Netto, Jair Machado , Kirkland, James L. , Tchkonia, Tamar , Lazaridis, Konstantinos N. , Gores, Gregory J. , LaRusso, Nicholas F.

Mayo Clinic

Journal of Gastroenterology and Hepatology | February 14, 2026 | Volume: 41 | Issue: 3 | Pages: 1065-1076

10.1111/jgh.70279 | PMID 41689244 Get It

ABSTRACT Background and Aims Cellular senescence is a hallmark of several liver diseases, including primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC). Senescent cholangiocytes exhibit a senescence‐associated secretory phenotype (SASP), characterized by profibroinflammatory mediator release. Current cost‐effective biomarkers predicting disease progression, particularly for PSC, are limited and often lack mechanistic relevance. We sought to define a plasma biomarker signature for PSC and PBC. Methods Plasma from early‐ and late‐stage PSC and PBC, alcoholic liver disease (ALD), inflammatory bowel disease (IBD) patients, and healthy controls was analyzed. Seventy‐one analytes were quantified using Luminex Multiplex Immunoassay or enzyme‐linked immunosorbent assay (ELISA). Principal component analysis (PCA) identified key patterns. Findings from the PSC cohort were then applied to additional cohorts. Results Second principal component (PC2) (17 analytes, 17.1% variability) best separated PSC from controls. ANOVA showed significant differences in PC2 between early PSC vs. controls ( p = 0.0001), late PSC vs. controls ( p < 0.0001), and early vs. late PSC ( p < 0.0001). PC2 analytes also distinguished early PBC vs. controls ( p < 0.0332), late PBC ( p < 0.0001), and ALD ( p < 0.0001), and early vs. late PBC ( p < 0.0001), but not IBD vs. controls ( p = 0.119). Logistic regression using PC2 demonstrated strong discrimination of early‐ and late‐stage PSC (AUC = 0.86) and control vs. early‐stage PSC (AUC = 0.83). Conclusion This is the first study to define a plasma SASP biomarker signature associated with cholestatic liver disease. These analytes track disease stage and represent both mechanistic indicators and potential clinical trial endpoints.
Prognostic Model for Progression of Autosomal Dominant Polycystic Kidney Disease to Kidney Failure
Cohen, Aarón , Landsittel, Douglas , Chapman, Arlene B., Mrug, Michal , Bae, Kyongtae T., Yu, Alan S.L. , Ables, Erin , Torres, Vicente E. , Chebib, Fouad T. , Harris, Peter C. , Rahbari-Oskoui, Frederic F. , Dickinson, Stephanie , Bennett, William M. , Landsittel, Douglas P.

Mayo Clinic

Journal of the American Society of Nephrology | May 17, 2024 | Volume: 34 | Issue: 11S | Pages: 209-209

10.1681/asn.20233411s1209c Get It

Whole‐body senescent cell clearance alleviates age‐related brain inflammation and cognitive impairment in mice
Ogrodnik, Mikołaj , Evans, Shane A., Fielder, Edward , Victorelli, Stella , Krüger, Patrick, Salmonowicz, Hanna , Weigand, Bettina M., Patel, Ayush , Pirtskhalava, Tamar , Inman, Christine, Johnson, Kurt O. , Dickinson, Stephanie , Rocha, Azucena, Schafer, Marissa , Zhu, Yi , Passos, João F. , Kirkland, James L. , Jurk, Diana , Patel, Ayush D, Inman, Christine L, Schafer, Marissa J, Jurk, Diana , Passos, João F , Schafer, Marissa J , Zhu, Yi , Allison, David B. , Zglinicki, Thomas von , LeBrasseur, Nathan K. , Tchkonia, Tamar , Neretti, Nicola

Mayo Clinic

Aging Cell | January 20, 2021 | Volume: 20 | Issue: 2 | Pages: No page available

10.1111/acel.13296 | PMID 33470505 Get It

Abstract Cellular senescence is characterized by an irreversible cell cycle arrest and a pro‐inflammatory senescence‐associated secretory phenotype (SASP), which is a major contributor to aging and age‐related diseases. Clearance of senescent cells has been shown to improve brain function in mouse models of neurodegenerative diseases. However, it is still unknown whether senescent cell clearance alleviates cognitive dysfunction during the aging process. To investigate this, we first conducted single‐nuclei and single‐cell RNA‐seq in the hippocampus from young and aged mice. We observed an age‐dependent increase in p16 Ink4a senescent cells, which was more pronounced in microglia and oligodendrocyte progenitor cells and characterized by a SASP. We then aged INK ‐ ATTAC mice, in which p16 Ink4a ‐positive senescent cells can be genetically eliminated upon treatment with the drug AP20187 and treated them either with AP20187 or with the senolytic cocktail Dasatinib and Quercetin. We observed that both strategies resulted in a decrease in p16 Ink4a exclusively in the microglial population, resulting in reduced microglial activation and reduced expression of SASP factors. Importantly, both approaches significantly improved cognitive function in aged mice. Our data provide proof‐of‐concept for senolytic interventions' being a potential therapeutic avenue for alleviating age‐associated cognitive impairment.